FDA Says No Error In Agency’s Decision To Remove Tirzepatide From Shortage List
NEW ORLEANS — Companies representing the interests of drug compounders “offer no sound reason to second-guess FDA’s reasonable determination” that the shortage of tirzepatide, an FDA-approved drug for diabetes and weight...To view the full article, register now.
Already a subscriber? Click here to view full article